Oligomers of the lipodystrophy protein seipin may co-ordinate GPAT3 and AGPAT2 enzymes to facilitate adipocyte differentiation. by Sim, MF Michelle et al.
1Scientific RepoRtS |         (2020) 10:3259  | https://doi.org/10.1038/s41598-020-59982-5
www.nature.com/scientificreports
oligomers of the lipodystrophy 
protein seipin may co-ordinate 
GPAT3 and AGPAT2 enzymes to 
facilitate adipocyte differentiation
M. f. Michelle Sim1,4, Elisa persiani2,4, Md. Mesbah Uddin talukder3, George D. Mcilroy  2, 
Ahlima Roumane2, J. Michael edwardson3 & Justin J. Rochford  1,2*
Seipin deficiency causes severe congenital generalized lipodystrophy (CGL) and metabolic disease. 
However, how seipin regulates adipocyte development and function remains incompletely understood. 
We previously showed that seipin acts as a scaffold protein for AGPAT2, whose disruption also 
causes CGL. More recently, seipin has been reported to promote adipogenesis by directly inhibiting 
GPAT3, leading to the suggestion that GPAT inhibitors could offer novel treatments for CGL. Here 
we investigated the interactions between seipin, GPAT3 and AGPAT2. We reveal that seipin and 
GPAT3 associate via direct interaction and that seipin can simultaneously bind GPAT3 and AGPAT2. 
Inhibiting the expression of seipin, AGPAT2 or GPAT3 led to impaired induction of early markers of 
adipocyte differentiation in cultured cells. However, consistent with normal adipose mass in GPAT3-
null mice, GPAT3 inhibition did not prevent the formation of mature adipocytes. Nonetheless, loss 
of GPAT3 in seipin-deficient preadipocytes exacerbated the failure of adipogenesis in these cells. 
Thus, our data indicate that GPAT3 plays a modest positive role in adipogenesis and argue against the 
potential of GPAT inhibitors to rescue white adipose tissue mass in CGL2. Overall, our study reveals 
novel mechanistic insights regarding the molecular pathogenesis of severe lipodystrophy caused by 
mutations in either seipin or AGPAT2.
Individuals with loss-of-function mutations in the BSCL2 gene, encoding the protein seipin, suffer from congen-
ital generalised lipodystrophy type 2 (CGL2) and severe metabolic disease1,2. This phenotype appears to result at 
least in part from a reduced capacity to develop adipocytes from precursor cells as well as a failure to maintain 
functional mature adipocytes3–10. Seipin is highly conserved evolutionarily; it is principally localised to the endo-
plasmic reticulum (ER) membrane and forms highly organised homo-oligomers11–15. This has led to investigation 
of seipin as a potential scaffold protein and the identification of several seipin-binding proteins involved in lipid 
droplet biology and adipocyte development and function16. We previously showed that seipin can simultaneously 
bind to both AGPAT2 and lipin 1, key pro-adipogenic enzymes that act sequentially in the same lipid biosynthetic 
pathway17,18. A more recent study reported that seipin can also bind to GPAT enzymes, which catalyse the step 
immediately preceding that catalysed by AGPAT219. The authors demonstrated that seipin can act as an inhibitor 
of the glycerol-3-phosphate acyltransferase activity of GPAT3 and proposed that the loss of this inhibition leads 
to impaired adipocyte differentiation when seipin is absent19. Moreover, they reported that pharmacological inhi-
bition of GPAT3 could partly rescue adipogenesis in seipin-deficient preadipocytes and so might offer a potential 
therapy for the treatment of patients with CGL219. However, these data partly contradict a previous study showing 
that GPAT3 positively regulates adipogenesis in cultured preadipocytes20, leading us to examine this issue further. 
In this study we confirm the observation that seipin binds GPAT3 and use atomic force microscopy (AFM) to 
reveal that this involves direct contact between the two proteins. Moreover, we find that seipin can increase the 
interaction between GPAT3 and AGPAT2, suggesting that seipin oligomers can scaffold these two proteins in a 
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single complex. However, we did not find that inhibition of GPAT3 could rescue adipogenesis in cells lacking 
seipin, nor that increased GPAT3 expression impaired adipocyte development. Our results, therefore, question 
the notion that inhibition of GPAT3 could offer a potential therapeutic option for the treatment of CGL2.
Results
Seipin can associate with GPAT3 in developing adipocytes. To confirm the reported interaction of 
seipin with GPAT enzymes and examine whether either the short or long form of seipin preferentially binds these 
enzymes, we co-expressed FLAG-tagged human seipin with either Myc-tagged human GPAT3 (Fig. 1A) or Myc-
tagged human GPAT4 (Fig. 1B). GPAT3 or GPAT4 could clearly be detected in anti-FLAG immunoprecipitates 
using either the long or short forms of seipin, demonstrating that both GPAT enzymes can interact with either 
isoform of seipin. Previous studies have indicated that GPAT3 may constitute the more significant microsomal 
GPAT activity in adipocytes and have a greater role than GPAT4 in the differentiation of 3T3-L1 adipocytes20,21. 
Meanwhile, GPAT4 may play important roles in regulating lipid metabolism and insulin sensitivity in the liver22. 
In similar experiments using C3H10T1/2 cells undergoing adipogenesis, we specifically inhibited the expres-
sion of either GPAT3 (Fig. S1A) or GPAT4 (Fig. S1B) using siRNA. GPAT3 knockdown was more effective than 
GPAT4 knockdown at inhibiting the expression of key markers of adipogenesis, including PPARγ and C/EBPα 
(Fig. S1C,D). In light of these data and previously published work, we focussed on the interaction of seipin with 
GPAT3 as this is likely to be most relevant to the regulation of early adipogenesis.
As we had previously reported the interaction of seipin with AGPAT218, we also compared the binding of 
seipin to either GPAT3 or AGPAT2. We typically observed slightly higher expression of AGPAT2 versus GPAT3 
in these experiments making accurate, direct comparison difficult. However, overall we observed that the capacity 
of seipin to interact with either protein appeared similar (Fig. S1E)
To further validate the interaction between GPAT3 and seipin we turned to bimolecular fluorescence comple-
mentation (BiFC) analysis. The C-terminal portion of YFP (Yc) was fused to either the N or C terminus of GPAT3 
to generate Yc-GPAT3 or GPAT3-Yc, respectively. Similarly, the N-terminal portion of YFP (Yn) was fused to 
the N or C terminus of seipin to generate Yn-seipin and seipin-Yn, respectively. Co-expression of GPAT3-Yc and 
seipin-Yn led to YFP fluorescence within cells, indicating an association between GPAT3 and seipin, (Fig. 1C,D). 
In contrast we detected no YFP fluorescence when cells were transfected with other combinations of seipin and 
GPAT3 fusion proteins, despite similar GPAT3 expression (Fig. 1C–E). The specific requirement for a particu-
lar orientation of half-YFP proteins implies a specific interaction between seipin and GPAT3 rather than any 
non-specific aggregation of these proteins. These data confirm the previous report that seipin and GPAT3 can 
interact19 using a different technique to analyse this interaction in intact cells.
We next examined the interaction between seipin and GPAT3 in developing adipocytes by co-transfecting 
3T3-L1 preadipocytes with seipin-Yn and GPAT3-Yc before inducing the cells to differentiate. Reconstituted YFP 
fluorescence could be clearly observed in these cells at day 3 of differentiation. The BiFC signal co-localized 
substantially with either GPAT3 or seipin expressed in the cells (Fig. 1F). We also transfected cells in an identical 
manner but omitted the temperature shift which is required to generate YFP fluorescence in BiFC assays. This 
revealed significant co-localization of the seipin-Yn and GPAT3-Yc proteins (Fig. 1F, lower panels). We observed 
no fluorescent BiFC signal when seipin-Yn was co-expressed with Yc-GPAT3 in differentiating 3T3-L1 adipo-
cytes, again indicating that the association between seipin and GPAT3 in developing adipocytes occurs with a 
defined orientation (Fig. S1F,G).
Seipin binds GPAT3 via its evolutionarily conserved core domains whilst pathogenic mutations 
in seipin can affect this interaction. In order to examine the domains of seipin relevant for the interaction 
with GPAT3 we used deletion mutants of seipin lacking either the cytoplasmic N (ΔNT) or C termini (ΔCT), the 
first (ΔTM1) or second (ΔTM2) transmembrane domains or the ER luminal loop region (Δloop) of the protein 
(Fig. 2A,B). While deletion of either N or C termini of seipin did not significantly inhibit its interaction of with 
GPAT3, loss of either the first or second transmembrane domain or the ER luminal loop region of seipin signif-
icantly reduced GPAT3 binding. This finding contrasts with the interaction between seipin and AGPAT2, which 
does not require an intact second transmembrane domain18, indicating that the interaction of these two proteins 
with seipin occurs independently of one another.
In order to examine whether altered interaction with GPAT3 might contribute to the failure of adipose devel-
opment in CGL2 patients we determined the capacity of GPAT3 to bind to pathogenic mutants of seipin bearing 
one of three single amino acid substitutions, T78A, L91P or A212P. All three mutant forms of seipin were able to 
co-immunoprecipitate GPAT3 (Fig. 2C). However, while the T78A mutant form of seipin was indistinguishable 
in this regard from wild-type seipin, the interaction of GPAT3 with L91P and A212P mutant forms of seipin was 
reduced by approximately 50% (Fig. 2C,D).
GPAT3 binds directly to oligomers of seipin. We next investigated the molecular architecture of seipin/
GPAT3 complexes using AFM. FLAG-GPAT3 was expressed in HEK-derived tsA 201 cells and immunoisolated 
(Fig. 3A), eluted and imaged by AFM (Fig. 3B). Analysis of the volumes of GPAT3 particles revealed a single 
peak at 127 ± 7 (mean ± SEM) nm3 (n = 100) (Fig. 3C), similar to the expected molecular volume of 104 nm3. 
FLAG-GPAT3 and seipin-Myc were then co-expressed and both proteins were subsequently detected in anti-Myc 
immunoprecipitates (Fig. 3D). Following elution of the co-immunoprecipitated proteins, AFM analysis revealed 
large particles with smaller, peripherally associated particles (Fig. 3E). Higher magnification images of these com-
plexes are shown in Fig. 3F. The peak molecular volume of the peripheral particles (114 ± 6 nm3; n = 120; Fig. 3G) 
was very similar to that of GPAT3 alone (Fig. 3C). The peak volume of the core of the complex was 2174 ± 38 nm3 
(n = 60; Fig. 3H). This is very similar to the volume of 2394 nm3 that we have reported for seipin dodecamers12. 
However, we note that human seipin has recently been reported to form 11-mers which could also be consistent 
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Figure 1. Seipin can associate with GPAT3 and GPAT4. HEK293 cells were transfected with GPAT3-Myc (A) 
or GPAT4-Myc (B) in the absence or presence of either the short (S) or long (L) forms of FLAG-tagged seipin. 
Lysates and anti-FLAG immunoprecipitates were analysed by SDS-PAGE and immunoblotting with antibodies 
to FLAG or Myc to detect tagged proteins or calnexin as a loading control. (C) HEK293 cells were transfected 
with constructs in which the N-terminal fragment of YFP was fused to the C or N terminus of seipin (S-Yn or 
Yn-S, respectively), and constructs in which the C-terminal fragment of YFP was fused to either the C or N 
terminus of GPAT3-Myc (G-Yc and Yc-G, respectively). A temperature shift was used to induce the formation of 
reconstituted YFP then cells were fixed and stained for GPAT3-Myc (red) and DAPI to label nuclei. The presence 
of a YFP signal (yellow) indicates an interaction between GPAT3 and seipin. Scale bars, 10 μm. (D) Quantified 
BiFC signal intensity. Errors are SEM (n = 3). ***Indicates a difference in YFP fluorescence compared with 
G-Yc/S-Yn (p < 0.001). (E) Anti-Myc immunoblot showing GPAT3-Yc and Yc-GPAT3 expression and calnexin 
as a loading control. (F) 3T3-L1 preadipocytes were co-transfected with FLAG-seipin-Yn and Myc-GPAT3-Yc 
immediately after the induction of differentiation. Three days later cells were fixed and anti-FLAG or anti-Myc 
antibodies were used to detect FLAG-seipin-Yn or Myc-GPAT3-Yc, respectively. Identically transfected cells 
were co-immunostained for FLAG-seipin-Yn and Myc-GPAT3-Yc (lower panels). However these latter cells 
were not temperature shifted so as to prevent the formation of YFP which would otherwise confound the use of 
Alexa Fluor488 labelled secondary antibodies in order to detect the FLAG epitope. Scale bars, 10 μm.
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with this molecular volume. Analysis of AFM images revealed that 10.4% (50/480) of seipin particles were deco-
rated by two GPAT3 particles, although complexes with one GPAT3 particle were more common. In contrast, no 
complexes bearing peripherally associated particles were seen when seipin was expressed alone (158 particles). 
We also analysed the distribution of angles between pairs of bound GPAT3 molecules, which showed a peak at 
87° ± 11° (n = 50; Fig. 3I). A toroidal, dodecameric arrangement of seipin oligomers should lead to an angle of 30° 
separation between individual seipin subunits12, whilst an 11-mer of seipin would result in an angle of 32.7° sep-
aration between subunits. Thus, our data imply that where two GPAT3 molecules bind to seipin subunits, these 
are typically separated by two unoccupied seipin subunits. Together, these AFM analyses show that oligomers of 
seipin can directly bind GPAT3, while the defined molecular architecture of these complexes indicates a highly 
ordered, specific interaction.
Inhibition of GPAT3 expression is unable to rescue seipin deficiency in differentiating adipocytes 
and GPAT3 overexpression does not impair adipogenesis. The previous report of reduced adipogen-
esis in cells lacking GPAT320, and our own data from preadipocytes in which GPAT3 was inhibited (Fig. S1A–D), 
appeared to directly contradict the more recent report that seipin may exert its proadipogenic effects by inhibiting 
GPAT319. Although they did not examine the effect of inhibiting GPAT3 on adipogenesis, the authors of the latter 
study did report that inhibition of GPAT3 expression could rescue adipogenesis in cells lacking seipin19. This led 
them to propose that inhibiting GPAT3 could offer a potential therapy for CGL2. We decided to examine this 
using knockdown of seipin (Bscl2) and/or Gpat3 by siRNA in C3H10T1/2 cells. Transfection with specific siRNA 
Figure 2. The conserved transmembrane and ER luminal loop regions of seipin are required for its interaction 
with GPAT3. (A) HEK293 cells were transfected with empty vector (−), wild-type Myc-seipin (WT) or mutant 
seipin lacking the N-terminus (ΔNT), the first transmembrane domain (ΔTM1), the ER luminal loop region 
(Δloop), the second transmembrane domain (ΔTM2) or the C-terminus (ΔCT) in the absence or presence 
of FLAG-tagged GPAT3 as indicated. Cell lysates or anti-FLAG immunoprecipitates were separated by SDS-
PAGE and immunoblotted with antibodies to FLAG, Myc and calnexin. (B) Quantification analysis of the 
binding of WT or mutant forms of seipin to FLAG-GPAT3. Data represent means ± SEM (n = 3), normalized to 
expression levels and expressed as a fold of that observed with wild-type seipin. * indicates p < 0.05, ** indicates 
p < 0.01 and *** indicates p < 0.001 versus co-immunoprecipitation with wild-type seipin. (C) HEK293 cells 
were transfected with empty vector (−), N-terminal FLAG-tagged wild-type seipin (WT) or identically-tagged 
T78A, L91P and A212P forms of seipin in the presence or absence of Myc-tagged GPAT3. Cell lysates or anti-
FLAG immunoprecipitates were separated by SDS-PAGE and immunoblotted with antibodies to FLAG, Myc 
and calnexin. (D) Quantification analysis of the binding of WT or mutant forms of seipin to Myc-GPAT3. Data 
represent the means ± SEM (n = 3), normalized to expression levels and expressed as a fold of that observed with 
wild-type seipin. * indicates p < 0.05, ** indicates p < 0.01 versus co-immunoprecipitation with wild-type seipin.
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two days prior to the induction of differentiation efficiently and selectively targeted either seipin (Fig. 4A) or 
Gpat3 (Fig. 4B) mRNA expression at day 0 when adipogenesis was induced. This was the case whether used alone 
or in combination. As shown previously in Fig S1B, our Gpat3-targetting siRNA does not affect the expression 
of Gpat4 mRNA prior to adipogenic induction. Inhibition of seipin or Gpat3 did not significantly affect Pparγ 
induction at this early stage of differentiation, but did lead to significant inhibition of C/ebpα, aP2 and Glut-4 
expression during early adipogenesis (Fig. 4C–F). When both Gpat3 and seipin were inhibited, this led to an even 
more marked reduction in the induction of these key markers of adipocyte differentiation. To determine whether 
this effect was sustained we also examined lipid accumulation in C3H10T1/2 cells in which seipin and/or Gpat3 
expression had been inhibited with siRNA followed by differentiation for 10 days. Inhibition of seipin expression 
significantly reduced total lipid accumulation in these cells (Fig. S2A,B). In contrast, lipid accumulation in cells 
in which Gpat3 expression had been inhibited was indistinguishable from that in control cells. However, Gpat3 
expression failed to rescue lipid accumulation in cells lacking seipin. Hence, whilst the initial impairment of 
adipogenic gene induction caused by Gpat3 inhibition did not ultimately cause a significant reduction in lipid 
accumulation, we found no evidence that additional loss of Gpat3 could rescue differentiation caused by the loss 
of seipin. As these data are at variance with the observations in the report from Pagac et al. we also performed 
experiments in the 3T3-L1 preadipocyte cell line used in their study19. This produced similar effects whereby 
siRNA-mediated inhibition of either seipin or Gpat3 (Fig. S3A,B) led to inhibition of the induction of the adipo-
genic markers Pparγ, C/ebpα, aP2 and Glut-4 (Fig. S3C–F). With the exception of Glut-4, additional inhibition of 
Figure 3. Seipin interacts with GPAT3 via direct physical contacts. (A) FLAG-GPAT3 was expressed in tsA 201 
cells and isolated using anti-FLAG beads. Following SDS-PAGE, isolated protein was analysed by either silver 
staining (left panel) or immunoblotting using an anti-FLAG antibody (right panel). (B) Zoomed images from 
AFM analysis of immunoisolated GPAT3 showing individual GPAT3 particles. (C) Frequency distribution of 
volumes of the GPAT3 particles. The curve indicates the fitted Gaussian function. The peak of the distribution 
(±SEM) is indicated. (D) tsA 201 cells were co-transfected with FLAG-GPAT3 and Seipin-Myc and proteins 
were isolated using anti-Myc beads. Proteins were separated by SDS-PAGE followed by immunoblotting 
using either anti-Myc (left panel) or anti-FLAG (right panel) antibodies. (E) Low-magnification image from 
AFM analysis of isolated proteins. The arrowhead indicates a large particle (seipin) decorated by one smaller 
(GPAT3) particle; the arrow indicates a seipin particle decorated by two GPAT3 particles. (F) Gallery of zoomed 
images showing seipin particles decorated by either one (left panels) or two (right panels) GPAT3 particles. 
(G) Frequency distribution of volumes of the smaller (GPAT3) particles with the curve indicating the fitted 
Gaussian function. The peak of the distribution (±SEM) is indicated. (H) Frequency distribution of volumes of 
the larger (seipin) particles. (I) Frequency distribution of angles between pairs of bound GPAT3 particles.
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Figure 4. Inhibition of Gpat3 expression fails to rescue adipogenesis in seipin-deficient cells, while GPAT3 
overexpression does not impair this process. C3H10T1/2 cells were transfected with control siRNA (−ve) 
or siRNA targeting seipin (Bscl2), Gpat3 or both seipin (Bscl2) and Gpat3 as indicated at day -2 and day 
0 of differentiation. RNA was extracted at day 0 or day 2 of differentiation and expression of Bscl2/seipin 
(A) Gpat3 (B) Pparγ (C) C/ebpα (D) aP2 (E) and Glut4 (F) was determined by qPCR. Data are presented 
as relative mRNA expression (means ± SEM, n = 4), normalized to the stable housekeeping gene Ywhaz. 
Statistically significant differences compared to control siRNA at each time point are indicated: * indicates 
p < 0.5, **p < 0.01, ***p < 0.001, ****p < 0.0001. Alternatively, cells were transfected at day -2 and day 0 of 
differentiation with empty vector or plasmids encoding seipin (BSCL2), GPAT3, or co-transfected with both 
seipin (BSCL2) and GPAT3, as indicated. RNA was isolated at day 0 or day 2 of differentiation and expression 
of BSCL2/seipin (G), GPAT3 (H), Pparγ (I), C/ebpα (J), aP2 (K) and Glut4 (L) determined by qPCR. Data are 
presented as means ± SEM, (n = 4), normalized to Ywhaz. Statistical analysis was made by one-way ANOVA 
followed by Dunnett’s multiple comparison post-hoc test. Statistically significant differences compared to 
control day 0 (Mock Day 0) are indicated by *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Statistically 
significant differences compared to control (Mock day 2) samples are indicated by ###p < 0.001, ####p < 0.0001. 
(M) Identically transfected cells were also differentiated for 3 days, fixed and immunostained to detect FLAG-
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Gpat3 exacerbated the inhibition of adipogenesis by seipin loss during early adipogenesis. We also repeated these 
experiments with an additional siRNA targeting seipin alone or in combination with two different siRNA target-
ing Gpat3. These alternative siRNA were not as effective at inhibiting seipin or Gpat3 expression (Fig. S3G,H). 
Nonetheless, we observed similar results to those obtained with the original combination of siRNA when the early 
induction of the adipogenic markers Pparγ, C/ebpα, aP2 and Glut-4 were examined following two days of differ-
entiation (Fig. S2G–L). Where the effect of combined knockdown differed from that of seipin or Gpat3 inhibition 
alone, this was to further impair the induction of these genes. We also verified that the second Gpat3 siRNA did 
not directly inhibit Gpat4 mRNA expression (Fig. S3M).
To further test whether GPAT3 might act as an inhibitor of adipogenesis we next determined the effect of 
overexpression of GPAT3 and/or seipin on adipocyte differentiation. Transfection of C3H10T1/2 cells with either 
FLAG-Seipin or Myc-GPAT3 prior to induction of differentiation led to their robust expression (Fig. 4G,H). 
When markers of adipogenesis were examined at day 3 of differentiation in these cells we observed significant 
induction of Pparγ, C/ebpα, aP2 and Glut-4 mRNA expression regardless of whether seipin, GPAT3 or both 
proteins were overexpressed (Fig. 4I–L). Critically we saw no evidence that GPAT3 overexpression inhibited adi-
pogenesis; rather this appeared to modestly enhance the process. As these data contradicted those of Pagac et al., 
we considered whether our use of transient transfection could mean that cells expressing GPAT3 have reduced 
adipogenesis but that this effect might be masked by untransfected cells in the cultures. Hence, we transfected 
cells with either FLAG-seipin or Myc-GPAT3 alone or in combination and then individually analysed the accu-
mulation of PPARγ in transfected versus untransfected cells in each culture, as a marker of adipogenic induction. 
In cultures of cells transfected with either FLAG-seipin, Myc-GPAT3 or both proteins, we observed no significant 
reduction in the overall fluorescence intensity of nuclear PPARγ staining between transfected and untransfected 
cells with any of the transfection conditions examined (Fig. 4M,N). Moreover, we transfected preadipocytes with 
GPAT3 before the induction of adipogenesis and then differentiated the cells to mature adipocytes. In agree-
ment with our data analysing nuclear PPARγ accumulation during early adipogenesis, the absence or presence of 
GPAT3 expression in individual cells had no detectable effect on the formation of mature adipocytes as assessed 
by the appearance of lipid droplets (Fig. 4O). Finally, having noted that GPAT3 overexpression may modestly 
increase the induction of adipogenic markers in C3H10T1/2 cells (Fig. 4I–L), we also examined the effect of 
GPAT3 overexpression in 3T3-L1 cells, the line used by Pagac et al.19. In 3T3-L1 cells transfected with human 
GPAT3, endogenous murine Gpat3 expression was unaffected but we observed significantly increased expres-
sion of Pparγ, C/ebpα, aP2, adiponectin and perilipin mRNA (Fig. S3N). Although we did not formally assay 
the specific activity of GPAT3 in these cells we believe these data strongly imply that the GPAT3 construct used 
in our studies is functionally active. Overall, we find no evidence that robust expression of GPAT3 leads to any 
inhibition of adipogenesis. Indeed our data suggests that GPAT3 expression may positively influence adipocyte 
development, consistent with the substantial induction of its expression during early adipogenesis.
Seipin can bind both AGPAT2 and GPAT3, facilitating the interaction between these key adipo-
genic enzymes. We have previously shown that seipin can bind AGPAT2, which uses the product of GPAT3 
activity, lysophosphatidic acid, as a substrate. Next, we employed BiFC analysis to investigate whether seipin 
might act as a scaffold to co-ordinate the association of these two enzymes. To do this, the N-terminal portion 
of YFP (Yn) was fused to the N or C terminus of AGPAT2 to generate Yn-AGPAT2 and AGPAT2-Yn. Similarly, 
the C-terminal portion of YFP (Yc) was fused to either the N or C terminus of GPAT3 to generate Yc-GPAT3 or 
GPAT3-Yc, respectively. All combinations of these fusion proteins were then expressed in HEK293 cells in the 
absence or presence of co-expressed seipin. Reconstituted YFP fluorescent signal was clearly detectable in cells 
expressing AGPAT2-Yn and GPAT3-Yc, specifically when seipin was co-transfected with these constructs but 
not when seipin was absent (Fig. 5A,B). However, no BiFC signal was detected when any other combination 
of AGPAT and GPAT3 BiFC constructs was used. To further test the specificity of this scaffolding function we 
compared the capacity of wild-type seipin and the mutant form of seipin lacking the ER luminal loop domain 
of the protein (ΔLP) to induce BiFC fluorescence when co-expressed with AGPAT2-Yn and GPAT3-Yc. This 
mutant form of seipin was chosen as it retains the transmembrane domains and has been shown to have the same 
overall structure and localisation as the wild-type protein23 but has reduced binding to GPAT3 (Fig. 2A,B) and 
AGPAT218. Despite equivalent expression of wild-type and ΔLP-seipin, the latter was not able to induce a BiFC 
signal between AGPAT2-Yn and GPAT3-Yc (Fig. 5C,D).
Inhibition of either seipin, AGPAT2 or GPAT3 impairs adipogenesis and prevents the early 
induction of Akt activity. As our data indicated that seipin, GPAT3 and AGPAT2 might act together in 
a co-ordinated manner, we directly compared the effects of inhibiting these three proteins in differentiating 
C3H10T1/2 cells. Inhibition of either seipin, Gpat3 or Agpat2 using siRNA (Fig. 6A–C) led to a significant reduc-
tion in the expression of the key adipogenic markers C/ebpα, aP2 and Glut-4 (Fig. 6D–F). It has previously been 
reported that loss of Akt activation during early adipogenesis may underpin the failure of adipocyte development 
in Agpat2 deficient preadipocytes24. We therefore examined whether this may be a common feature of seipin, 
Agpat2 and Gpat3 deficiency. While phosphorylation of Akt was significantly increased in C3H10T1/2 cells at 
seipin/BSCL2 (red) or Myc-GPAT3 (red), anti-PPARγ (green) and DAPI for nuclei (blue). Co-transfected cells 
were immunostained for myc-GPAT3. (N) Quantified PPARγ signal intensity in the nuclei of untransfected 
and transfected cells in 50 nuclei per group in two independent experiments. Scale bar, 20 µm. Data represent 
means ± SEM. (O) Representative image of C3H10T1/2 overexpressing GPAT3 fixed at day 5 of differentiation 
and immunostained with antibodies to Myc-GPAT3 (green) and LipidTox to visualize lipid droplets.
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day 2 of adipogenesis, inhibition of Agpat2 expression prevented this (Fig. 6G,H), consistent with the previous 
findings of Subauste et al.24. Inhibition of either seipin or Gpat3 expression also completely prevented the induc-
tion of Akt phosphorylation in these cells. Overall, these data are consistent with a model in which seipin, GPAT3 
and AGPAT2 act together in a co-ordinated manner to promote adipogenesis in the early stages of this process.
Discussion
In this study, we have confirmed a previous report that the protein seipin, which plays a critical role in adipose 
tissue development and maintenance in humans, can bind to the glycerol-3 phosphate acyltransferase enzymes 
GPAT3 and GPAT419. In addition, our data suggest that GPAT3 may be the more important of the GPATs during 
early adipogenesis, consistent with previous studies19,20. Hence, we focussed on the interaction between GPAT3 
and seipin, and whether the loss of this association could mediate some of the effects of seipin deficiency on adi-
pogenesis. Extending the studies of Pagac et al., we further define the regions of seipin required for the interaction 
with GPAT3 and show that the pathogenic A212P and L91P mutant forms of seipin have a reduced capacity to 
bind to GPAT3. We have previously reported that these two mutant forms of seipin are unable to appropriately 
form uniform oligomers in the same way as the wild-type protein, that they partially mislocalise to the nuclear 
envelope, and that they have modestly but significantly decreased expression in preadipocytes8,12. A combination 
of these factors, along with reduced binding to GPAT3, may explain the inability of these mutant forms to support 
adipose development in affected patients in the same way as wild-type seipin.
We were also able to demonstrate, using AFM analysis, that the interaction of GPAT3 with seipin involves 
direct contact between the two proteins. These data revealed that multiple molecules of GPAT3 could bind to a 
single seipin oligomer. The distribution of GPAT3 molecules bound to a single seipin oligomer was not random, 
Figure 5. Seipin potentiates the interaction between AGPAT2 and GPAT3. (A) HEK293 cells were co-
transfected with constructs in which the N terminus of YFP was fused to the N terminus (Yn-A) or C terminus 
(A-Yn) of AGPAT2-Myc, and with constructs in which the C-terminus of YFP was fused to the N terminus (Yc-
G) or C terminus (G-Yc) of GPAT3, in the absence or presence of FLAG-tagged seipin. Following a temperature 
shift to induce the formation of reconstituted YFP, cells were fixed and immunostained for Myc (AGPAT2) 
or FLAG (seipin), and DAPI to label nuclei. The interaction between AGPAT2 and GPAT3 is indicated by the 
presence of a YFP signal. Individual images are shown in grayscale and merged images show overlay of YFP 
(yellow) and AGPAT2-Myc or FLAG-seipin (red). Scale bars, 10 μm. (B) Quantified total BiFC signal intensity 
per image in 20 random images each of 3 separate experiments, normalized against a BiFC positive control, 
where cells were transfected with GPAT3-Yc and seipin-Yn. Data represent means ± SEM (n = 3). *** indicates 
p < 0.01 versus co-immunoprecipitation in the absence of seipin. (C) HEK293 cells were co-transfected with 
AGPAT2-Yn and GPAT3-Yc constructs in the presence of wild-type Myc-tagged seipin or identically-tagged 
mutant seipin lacking the loop domain (ΔLP). Following a temperature shift to induce the formation of 
reconstituted YFP, cells were fixed and stained for Myc-seipin and DAPI to label nuclei. The indirect interaction 
between AGPAT2 and GPAT3 in the presence of seipin is indicated by the presence of YFP signal. Individual 
images are shown in grayscale, and merged images show overlay of YFP (yellow) and Myc-seipin (red). Scale 
bars, 10 μm. (D) Quantified total BiFC signal intensity per image in 20 random images, each of 3 separate 
experiments. Data shown represent the means ± SEM (n = 3). *** indicates p < 0.001 versus BiFC signal 
observed in the presence of wild-type seipin.
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further demonstrating that the association between these two proteins is specific. Unfortunately, we were unable 
to use AFM to analyse whether single seipin homooligomers can bind to both GPAT3 and AGPAT2, as we have 
previously done for AGPAT2 and lipin 118. This experiment would require a significant difference in size between 
the proteins being analysed for them to be unequivocally distinguished from each other by AFM, and GPAT3 and 
AGPAT2 do not differ sufficiently in their molecular volumes. However, our BiFC analyses show that GPAT3 and 
AGPAT2 are extremely closely juxtaposed, selectively when seipin is present, indicating that they can indeed both 
bind to a single seipin oligomer.
In contrast to the findings of Pagac et al.19, we did not find that inhibiting GPAT3 could rescue adipogenesis in 
seipin-deficient cells. Indeed, additional loss of GPAT3 expression exacerbated the failure of adipocyte differen-
tiation in cultured cells under these conditions. We were also unable to detect any impairment of adipogenesis in 
preadipocytes overexpressing GPAT3, even when assessed at a single cell level. Indeed, overexpression of GPAT3 
modestly potentiated the induction of adipocyte genes in 3T3-L1 preadipocytes (Fig. S3N). The reason for this 
inconsistency is not clear but may relate to the levels of overexpression of GPAT3 in each study. Alternatively, 
we note that Pagac et al., used stably transduced cells and it is possible that the effects of long-term expression of 
GPAT3 in preadipocytes differs from the acute expression achieved in our model by transient transfection two 
days prior to adipogenesis. In a similar manner, we acutely inhibited seipin and/or GPAT3 in our double knock-
down experiments, whilst Pagac et al., used stably transduced cells. Again, the latter may lead to compensatory 
changes in the preadipocytes or effects that only manifest with sustained suppression of these genes during cell 
proliferation prior to the induction of adipogenesis. These may not be replicated in our experimental model by 
Figure 6. Inhibition of either seipin, Gpat3 or Agpat2 expression similarly inhibits adipogenesis. C3H10T1/2 
cells were transfected with control siRNA (−ve) or siRNA targeting seipin (Bscl2), Agpat2 or Gpat3 as indicated 
at day -2 and day 0 of differentiation. RNA was extracted at various time points and expression of seipin (Bscl2) 
(A) Agpat2 (B) and Gpat3 (C) C/ebpα (D) aP2 (E) and Glut4 (F) was determined by qPCR. Data represent 
means ± SEM (n = 4), normalized to Ywhaz. Statistical analysis was made with one-way ANOVA followed by 
Dunnett’s multiple comparison test. At each time point, significant differences between Bscl2 siRNA samples 
versus control siRNA samples are indicated by *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; between 
Gpat3 siRNA samples versus control siRNA samples by #p < 0.05, ##p < 0.01, ####p < 0.0001; and between 
Agpat2 siRNA samples versus control siRNA samples by °p < 0.05, °°p < 0.01, °°°p < 0.001, °°°°p < 0.0001. 
(G) Identically-transfected cells were lysed and analysed for total and phospho-Akt (Ser-473) levels by 
immunoblotting at either day 0 or day 2 of differentiation as indicated. Calnexin was used as a loading 
control. Full blots are shown in Fig. S4. (H) Quantification of the ratio of phosho-Akt to total Akt protein. 
Data represent means ± SEM (n = 3); expression is relative to total Akt levels in the same samples. Statistically 
significant differences from expression in control siRNA transfected cells (-ve) are indicated by *p < 0.05, 
**p < 0.01, ***p < 0.001.
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the acute inhibition of these genes in confluent cells immediately preceding adipogenesis. Whilst less likely in our 
view, it is also possible that differences in the levels of suppression achieved by each shRNA/siRNA in the different 
studies, or even off-target effects, could have led to the apparent discrepancies observed between the findings of 
Pagac et al., versus our data and the earlier work of Shan et al.20.
Our experiments revealed that seipin could facilitate the association of GPAT3 with AGPAT2, which can uti-
lise the product of GPAT3 in the same glycerolipid synthesis pathway. AGPAT2 is required for adipogenesis and 
its disruption, like that of seipin, causes CGL in affected patients. Loss of seipin, GPAT3 or AGPAT2 impaired 
adipogenesis in our analyses, although the effect of inhibiting GPAT3 was clearly less dramatic than the loss of 
either AGPAT2 or seipin. Overall, these results lead us to conclude that seipin may not act as an inhibitor of 
GPAT3 activity in the context of early adipogenesis. Rather, we speculate that seipin might potentiate adipocyte 
differentiation by scaffolding together the acyltransferases GPAT3 and AGPAT2 and the PA phosphatases lipin 1 
and/or 3, all of which positively regulate adipogenesis. This need not involve any alteration of the specific activity 
of each enzyme but rather facilitate co-localisation of these proteins, possibly permitting the efficient delivery of 
the product of each enzyme as substrates for the next within this single pathway.
In their study Pagac et al., used a variety of carefully performed and detailed enzymatic assays to demonstrate 
that seipin overexpression may lead to reduced GPAT activity in a variety of cell types19. Our findings do not 
necessarily contradict these results as, particularly in cells other than differentiating preadipocytes, there may 
be circumstances in which seipin performs this function. For example, seipin may sequester GPAT3 to a specific 
microdomain of the ER, reducing GPAT3 activity at the surface of lipid droplets. Similarly, seipin may impair the 
access of exogenous substrate to GPAT enzymes in these assays, leading to reduced detectable GPAT3 specific 
activity. Interestingly, it has been reported recently that elevated GPAT3 activity can mediate increased cellular 
stress in conditions of lipotoxicity25. This study examined the effect of exogenous lipid on non-adipose cells but 
clearly demonstrates the potential of increased GPAT3 activity to cause deleterious effects to cell function in some 
cell types. It will be interesting to determine whether seipin could alter the ability of lipids to induce cellular stress 
via GPAT3 inhibition in this context.
Our data, as those of Shan et al.20, show that inhibition of GPAT3 can impair the induction of some adipo-
cyte markers during the early stages of differentiation in cellular models of this process. However, we find that 
GPAT3 inhibition leads to a more modest impairment of adipogenesis than seipin or AGPAT2 loss, so that lipid 
accumulation and the expression of some adipogenenic marker genes such as C/ebpα and Glut4 are not signifi-
cantly reduced when analysed at later stages of adipogenesis (see Fig. S2A,B and Fig. 6D,E). Of note, GPAT3-null 
mice have apparently normal fat development, which is consistent with GPAT3 being less critical than seipin 
or AGPAT2 in the development of mature adipocytes and may even be entirely dispensable in vivo21. However, 
female, but not male, GPAT3-null mice have reduced adipose tissue expansion following high fat feeding which 
could result from a modestly reduced capacity to expand adipose tissues21. Whilst this manuscript was in revi-
sion, Gao and colleagues reported that additional disruption of GPAT3 can improve insulin tolerance and reduce 
hepatic steatosis in seipin-null mice26. Like seipin-null mice, mice lacking both GPAT3 and seipin exhibit a very 
striking reduction in white adipose tissue mass compared with control mice. However, BAT mass is increased in 
GPAT3/seipin double knockout mice and residual white adipose depots showed modestly increased mass and 
increased browning26. Thus, additional loss of GPAT3 appears to increase BAT development and improves meta-
bolic health without substantially rescuing white adipogenesis in this model of CGL2.
GPAT4-null mice show reduced body weight, increased energy expenditure and reduced adipose expansion 
in response to a high fat diet with a notable loss of subdermal adipose tissue27. This may particularly reflect an 
important role for GPAT4 in lipid storage versus oxidation in brown adipose tissue where it is highly expressed27,28. 
The complexity of these cellular and in-vivo phenotypes may result from differential roles of each isoform in regu-
lating adipogenesis in different adipose depots in combination with additional roles in triglyceride synthesis and 
lipid oxidation. More targeted models of GPAT disruption in vivo will be required to clarify how findings from 
cultured cells, including those presented here, translate to their function in both murine and human adipose tis-
sue in vivo. AGPAT2 deficiency leads to the loss of nearly all adipose depots in humans but so-called “mechanical” 
depots are spared29. However, while all WAT depots are absent in seipin-deficient CGL patients, including those 
spared in AGPAT2 deficiency, seipin appears dispensable for BAT development, at least in mice7,30,31. Thus, it is 
increasingly apparent that the pathways governing the development and expansion of adipose mass differs signif-
icantly between depots depending on location and the identity of the stem cells involved32,33. Such complexity is 
also likely to apply when considering the roles of different GPAT isoforms in these processes.
Several studies have examined the evolutionarily conserved role of seipin in lipid droplet biogenesis. GPAT3 
and GPAT4 have important roles in lipid droplet growth in multiple cells, including adipocytes. In particular, 
GPAT4 has been shown to accumulate on lipid droplets during droplet expansion34. Seipin has been shown 
to partly localize to ER-LD contact sites, and so may be involved in recruitment of GPAT and other lipogenic 
enzymes to this location to alter lipid droplet biogenesis, growth or budding14,35. In addition to GPATs, AGPAT2 
and lipins, a range of other proteins have been identified as seipin interacting partners that may regulate lipid 
droplets in multiple cell types and species. These include ADRP, SERCA2A, 14-3-3β, perilipin, promethin and 
Reep1 in mammalian cells17–19,36–41 and Pet10p, Ldo45 and Ldo16 in yeast42–44. In addition, two groups have 
recently reported the structure of seipin homo-oligomers determined by cryo-EM. The first examined the 
Drosophila form of the protein and revealed a 12-subunit complex13. The authors proposed an elegant model 
whereby these may scan the ER for nascent LD structures. Moreover, seipin oligomers may have an unusual 
capacity to switch conformation to adapt to the membrane structures that occur at these ER-LD interfaces. In 
this way they may act principally as physical controllers to regulate droplet dynamics. Alternatively, seipin may 
be able to perform this scanning role but also recruit appropriate binding partners to influence droplet size or 
composition. A second study using cryo-EM has reported that human seipin forms 11-subunit oligomers15. Our 
own studies using AFM suggest 12 subunits12. However, both the distribution of molecular volumes and the 
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distributions of angles we observed between antibodies bound to seipin homo-oligomers could allow for either 
11-mers or 12-mers12. The differences between our findings by AFM and cryo-EM analysis of human seipin might 
also reflect the expression and isolation methods used in each case. Yan et al. also showed that seipin may act as 
a phospholipid binding protein15. This could influence membrane curvature and so contribute to the ability of 
seipin to affect LD dynamics. It is not clear whether the evolutionarily conserved role of seipin in the regulation 
of lipid droplets is related to or distinct from its critical role in adipocyte differentiation. It seems credible that 
seipin’s capacity to structurally adapt to LDs and its interaction with LD proteins do not directly affect the process 
of adipogenesis. Meanwhile, the interaction with enzymes important for adipogenesis and LD function, such as 
GPATs, AGPAT2 and lipins may underlie the requirement for seipin in adipogenesis or have relevance to both 
functions.
Overall, our data confirm the previous report that seipin can bind to GPAT3. We reveal that this interaction 
involves direct association between the two proteins and present evidence that seipin oligomers may scaffold 
together both AGPAT2 and GPAT3 in a single multi-protein complex. However, we find no evidence that the loss 
of seipin causes a failure of adipogenesis due to increased GPAT3 activity. Rather our data support earlier work 
indicating that GPAT3 activity positively regulates adipocyte differentiation. Together, we believe that our work 
supports a model whereby seipin oligomers act as a scaffold for AGPAT2 and GPAT3, co-ordinating their proadi-
pogenic activities. Importantly, they also suggest that, whilst there is recent evidence that inhibiting GPAT3 might 
improve some metabolic parameters in BSCL2 deficiency, this is unlikely to substantially increase white adipose 
tissue mass in CGL2 patients.
Materials and Methods
cell culture. HEK293 cells were grown in DMEM containing 10% FBS and transiently transfected using cal-
cium phosphate precipitation or Fugene 6 transfection reagent (Promega) as in12. C3H10T1/2 cells and 3T3-L1 
preadipocytes were maintained and differentiated as described previously17. Differentiating adipocytes were tran-
siently transfected as in17 using lipofectamine LTX (Invitrogen). Transient knockdown in 3T3-L1 or C3H10T1/2 
cells was carried out using Lipofectamine RNAiMAX transfection reagent (Life Technologies), two days prior to 
and at the induction of adipogenesis, following the manufacturer’s protocol. siRNAs were from ThermoFisher 
Scientific (with catalogue numbers) as follows: Control siRNA (4390844), Bscl2 #1 (s66847), Bscl2 #2 (s66848), 
Gpat3 #1 (s106867), Gpat3 #2 (s106865), Agpat2 (s85202). For BiFC experiments, 3T3-L1 or HEK293 cells were 
cultured on glass coverslips, and transfected with S-Yn, Yn-S, G-Yc and Yc-G plasmids using Lipofectamine LTX 
(Invitrogen) or Fugene 6 (Roche), respectively. Cells were maintained at 37 °C for 4 h, then at 32 °C for 20 h and 
then at 30 °C for 2 h. Cells were harvested or fixed, permeabilized, blocked and analysed as previously described17. 
For AFM experiments, tsA 201 cells were cultured in DMEM supplemented with 10% FBS and transfected using 
calcium phosphate precipitation. Cells in 5 × 162 cm2 culture flasks were transfected with 250 μg of DNA, and 
cells were harvested after 48 h and used to immunoprecipitate proteins for AFM analysis.
constructs. Constructs to express FLAG-seipin, FLAG-AGPAT2, FLAG-GPAT3 and FLAG-seipin-Myc 
were generated in the pCMV3xFLAG vector (Sigma Aldrich). Seipin-Myc, GPAT3-Myc, GPAT4-Myc and 
AGPAT2-Myc were in the pcDNA3.1MycHis vector (LifeTechnologies), as previously described8,12,17,45. Fusion 
constructs for BiFC experiments were generated essentially as in17. Briefly, the N-terminal (1–158) fragment of 
YFP was inserted downstream or upstream of seipin in pCMV3xFLAG to generate S-Yn and Yn-S fusion con-
structs, respectively. Similarly, the N-terminal fragment of YFP was inserted upstream or downstream of AGPAT2 
or AGPAT2-Myc to generate tagged and untagged forms of A-Yn and Yn-A fusion proteins. The C-terminal 
(155–239) fragment was amplified and inserted downstream or upstream of GPAT3 or GPAT3-Myc to generate 
G-Yc and Yc-G fusion constructs, respectively.
Immunoprecipitations and immunoblotting. Lysates and anti-FLAG or anti-Myc immuno-
precipitates were prepared as described in12,17. HEK293 cells were transfected and 48 h later lysed in 
n-octyl-β-D-glucopyranoside (ODG) lysis buffer comprising 50 mM ODG, 50 mM Tris, pH 6.8, 150 mM NaCl, 
1 mM EDTA with protease inhibitors (Complete EDTA-free, Roche Applied Science) and phosphatase inhibitor 
cocktails (Sigma). Cells were sonicated for two cycles of 30 s at medium intensity, incubated for 20 min on ice, 
centrifuged at 16,000 g for 10 min at 4 °C and supernatants removed for use. Lysate containing 1 mg of protein was 
incubated with 30 μl of anti-FLAG-agarose beads (Sigma-Aldrich) which had been pre-equilibrated with ODG 
lysis buffer in a total volume of 800 μl. Following rotation for 2 h at 4 °C, samples were centrifuged (8,200 g for 30 s 
at 4 °C), supernatants were removed and beads washed three times with ODG lysis buffer and any excess buffer 
removed. FLAG-tagged proteins were recovered from beads using 200 ng/μl 3×FLAG peptide (Sigma-Aldrich) 
in TBS (50 mM Tris–HCl, pH 7.4, 150 mM NaCl) and incubated at 4 °C with rotation for 30 min. After cen-
trifugation supernatants were transferred to new tubes. 20 μg of lysate and 20 μl of IP samples were incubated 
with lithium dodecyl sulfate (LDS) sample buffer (Invitrogen). Samples were heated to 95 °C for 5 min, except 
those to be probed for seipin, and then separated by SDS-PAGE and transferred onto nitrocellulose membranes. 
Immunoblots were probed with antibodies to FLAG (Sigma), Myc (clone 4A6 Millipore), Akt, Phospho-Akt 
(Ser-473) (Cell Signaling) or calnexin (Abcam), followed by horseradish peroxidase (HRP)-linked secondary 
antibodies (Cell Signaling & Thermo Scientific) and visualized by ECL.
BiFC, immunofluorescence and lipid staining. Antibodies used in immunofluorescence analyses were 
as described above for immunoblotting. Highly cross-absorbed Alexa Fluor anti-mouse 488, anti-mouse 594 or 
anti-rabbit 594 secondary antibodies were used for detection (Invitrogen). Image acquisition and quantifica-
tion of BiFC signals were as described in17. For Oil red O analysis of neutral lipid accumulation in adipocytes, 
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following fixation, cells were treated with Oil Red O 0.1% solution further diluted in dH2O (6 parts Oil Red 
O 0.1% in 4 parts dH2O). Images were taken at Olympus IX-50 inverted microscope, 10 × magnification. B). 
Neutral lipid content was then quantified following spectrophotometric reading at 520 nm with SpectraMax 190 
(Molecular Devices).
AfM imaging of isolated proteins. tsA 201 cells were transfected, lysed and proteins isolated by immu-
noprecipitation using anti-Myc, anti-HA or anti-FLAG agarose as described in46. Imaging of isolated proteins was 
performed using ‘tapping’ mode in air, as described previously (23). Nanoscope software was used to manually 
determine particle heights and diameters and used to calculate the molecular volume of each particle using the 
equation:
pi= +V h r h( /6) (3 ) (1)m
2 2
where h is the particle height and r is the radius47. This equation assumes that the adsorbed particles adopt the 
form of a spherical cap. Molecular volume based on molecular mass was calculated using the equation:
= +V M N V dV( / )( ) (2)c 0 0 1 2
where M0 is the molecular mass, N0 is Avogadro’s number, V1 and V2 are the partial specific volumes of particle 
(0.74 cm3/g) and water (1 cm3/g), respectively, and d is the extent of protein hydration (taken as 0.4 g water/g 
protein).
Statistical analysis. Data are presented as mean ± SEM as indicated in the figure legends. Differences 
between groups were analysed with ANOVA followed by a Tukey’s post-hoc test or Dunnett’s multiple compari-
son post-hoc test as indicated. P < 0.05 was considered statistically significant.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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